IOncology

The 2024 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO-GU) was held from January 25th to 27th in San Francisco, showcasing the most innovative scientific advancements in the field and discussing future treatment directions for genitourinary cancers. Among them, several groundbreaking studies in the field of kidney cancer were presented, and "Oncology Frontier" invited Professor Xinan Sheng and Professor Xieqiao Yan from Peking University Cancer Hospital to interpret these studies for readers.

The ASCO-GU 2024, a major event in the field of urologic oncology, was held in San Francisco, USA, showcasing numerous innovative research advancements and discussing future treatment directions for urologic and male reproductive system tumors. For patients with non-muscle invasive bladder cancer (NMIBC) who do not respond to Bacillus Calmette-Guérin (BCG) treatment, there remains a need to find effective tools to detect the risk of recurrence or progression after second-line bladder-sparing treatments. During the conference, Professor Marie-Pier St-Laurent from the University of British Columbia presented the latest advancements in using whole-genome analysis of urinary tumor DNA (utDNA) to identify minimal residual disease (MRD) and quantify genomic changes, sharing in-depth insights in an interview with Oncology Frontier.

Hosted jointly by the Chinese Society of Clinical Oncology (CSCO) and the Beijing Hisco Clinical Oncology Research Foundation, the 2024 CSCO Guidelines Conference was held in Jinan on April 26-27. It is understood that updates to the CSCO guidelines for kidney cancer treatment are currently under discussion. "Oncology Frontier" interviewed Professor Pei Dong from the Sun Yat-sen University Cancer Center at the venue to interpret the upcoming updates to the new CSCO guidelines for kidney cancer treatment.

The 6th Precision Oncology Summit and the 9th Individualized Breast Cancer Treatment Conference (2023 COMB) were held from December 23 to 26, 2023, in a hybrid online and offline format. Professor Yuan Peng from the Cancer Hospital of the Chinese Academy of Medical Sciences delivered a lecture on "Precision Diagnosis and Treatment Strategies for Young Breast Cancer". After the conference, Oncology Frontier conducted an exclusive interview with Professor Yuan, where she shared her experiences related to the diagnosis and treatment of young breast cancer.

Triple-negative breast cancer (TNBC) is a highly aggressive and heterogeneous subtype of breast cancer, accounting for 15% to 20% of all breast cancers. Compared to other subtypes, TNBC patients often experience rapid clinical progression, are diagnosed at a younger age, have faster distant recurrence, and more common visceral metastasis. Treatment for TNBC is usually limited to chemotherapy, resulting in a poorer prognosis. With the breakthroughs in immune checkpoint inhibitors in the field of oncology, TNBC, as a relatively "hot" subtype among the otherwise immune "cold" tumors, has become a focus of research, showing improved therapeutic effects. Furthermore, neoadjuvant treatment, as a pre-surgical intervention for breast cancer, which aims to "downstage and conserve the breast" and acts as "in vivo drug sensitivity testing," has also received considerable attention in recent years. At the 2023 COMB conference, Professor Qiao Li from the Cancer Hospital of the Chinese Academy of Medical Sciences reviewed the current state and future of TNBC neoadjuvant research. Subsequently, the "Oncology Frontier" magazine invited Professor Li to discuss the progress and future directions of TNBC neoadjuvant treatment.

In recent years, the incidence and mortality rates of prostate cancer in China have been rapidly increasing. Early diagnosis and treatment are crucial, with prostate biopsy histopathology being the gold standard for diagnosis. However, differences in equipment and technical levels among medical institutions in China pose challenges for prostate biopsies, including issues with technique selection and operational standards. On January 6, 2024, the "2024 Beijing Genitourinary Tumor Youth Forum" was successfully held in Beijing, jointly hosted by the Urology Male Reproductive Tumor Professional Committee of the Beijing Anti-Cancer Association and the Beijing Medical Awards Foundation. Professor Gang Song from the National Cancer Center/Chinese Academy of Medical Sciences Cancer Hospital's Department of Urology delivered a fascinating speech titled "Consensus on Targeted Prostate Biopsy at Panjiayuan by National Cancer Center (English)" and discussed the background, clinical significance, and challenges of the consensus in an interview with "Oncology Frontier."

From April 14 to 17, 2024, the 50th European Society for Blood and Marrow Transplantation (EBMT) annual meeting was grandly held in Glasgow, UK. The conference focused on the latest advancements in stem cell transplantation and cellular therapy, pushing forward better clinical outcomes for patients with blood diseases and hematologic malignancies. In this issue, we are honored to have Professor Linhua Yang share selected advancements in the fields of allogeneic hematopoietic stem cell transplantation and cellular immunotherapy. We welcome our readers to engage and share their insights.

The 6th Precision Oncology Summit and the 9th Individualized Breast Cancer Treatment Conference (2023 COMB) took place from December 23 to 26, 2023, combining both online and offline formats. During the event, Professor Fei Ma from the Cancer Hospital of the Chinese Academy of Medical Sciences delivered an insightful presentation titled "The Knowns and Unknowns of Breast Cancer Immunotherapy." Following his presentation, Oncology Frontier conducted an exclusive interview with Professor Ma to discuss the latest advancements in breast cancer immunotherapy.

From January 5-6, 2024, the "Northern Breast Cancer Salon Annual Review and 2024 CSCO BC Guidelines Update Discussion" was held in Beijing. During the session on "Targeted Treatment-TNBC," Professor Qiang Liu from Sun Yat-sen Memorial Hospital of Sun Yat-sen University presented a report on "Progress in the Treatment of Early Triple-Negative Breast Cancer (TNBC)." After the session, "Oncology Frontier" conducted an exclusive interview with Professor Liu on the treatment of patients with early TNBC. The detailed content is organized below.